Kilitch Drugs India has reported results for fourth quarter ended March 31, 2012
The company has posted a fall of 10.94% in its net profit at Rs 78.92 crore for the quarter ended March 31, 2012 as compared to Rs 88.62 crore for the same quarter in the previous year. Total income has decreased by 84.66% at Rs 16.39 crore for quarter under review as compared Rs 106.82 crore for the quarter ended March 31, 2011
For the full year ended March 31, 2012, on the consolidated basis, the company has posted a rise of 729.87% in its net profit at Rs 86.97 crore for the year ended March 31, 2012 as compared to Rs 10.48 crore for the same period in the previous year. However, total income has decreased by 25.63% at Rs 108.80 crore for year under review as compared to Rs 146.30 crore for the period ended March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: